PΣPP {X}

Account#2 Just me & my 💬 |NFA| ✝️ | Libran ♎️ | ISO20022 | 🐺

[Arthur Britto @ahbritto]

😶

[PΣPP {X} @_MrYoshi]

Have you thought that this new Pope is tied to Globalism, or am I the only one?

[PΣPP {X} @_MrYoshi]

@unknowDLT A lot of gurus talked for years about halvings and altseasons every four years, without understanding that this market was made for utility. What they experienced before were siren songs.

[PΣPP {X} @_MrYoshi]

@UpholdInc @v0lta888 Damn

[PΣPP {X} @_MrYoshi]

@unknowDLT Do you think a world war will be needed for Xrp to get this level?

[PΣPP {X} @_MrYoshi]

@Shaggyz5150 Some regulated exchanges could replace them. Yes, not all will survive, in my opinion. Then, crypto projects like Lcx; Telcoin or BankSocial could have an opportunity.

[PΣPP {X} @_MrYoshi]

Banks aren't done; they're becoming blockchain. This means fewer operational problems, more benefits, and lower costs.

Don't be naive.

[Art of Information @artofinfo]

WORLD CUP 2026

[𝕀ℕ 🌻 @Ianbins]

Bread and circuses ….. 😉 #FIFAworldcup

[PΣPP {X} @_MrYoshi]

@EsotericKang It could be an economic war disguised as a military one. Perhaps it's necessary to reach a point of need, a level large enough to implement measures that improve the situation. I create the problem for you and then present you with the solution. The same old story.

[SMQKE @SMQKEDQG]

Yes, Ripple is integrated with DBS Bank and the XRP Ledger can tokenize gold.✅

Gold = $35 Trillion 💰

Documented.📝👇

[PΣPP {X} @_MrYoshi]

@RemiReliefX @RemiRelief2 I see $ZBCN @Zebec_HQ.

Mastercard, Solana, Anchorage, Stripe trough @privy_io and Ripple are involved with them. 🤭

DYOR.

[Stellar @StellarOrg]

.@Mastercard is expanding its settlement capabilities with additional intraday, weekend and holiday card settlement using regulated stablecoins.

Programmable, always-on payments now on Stellar.

[PΣPP {X} @_MrYoshi]

@ghostweb3 @CoinDesk @solana Good for $ZBCN

[PΣPP {X} @_MrYoshi]

SWIFT > ISO20022 > Crosschains and as result: Interoperability.

[Swift @swiftcommunity]

Interoperability is everywhere in discussions on tokenisation – but what does it mean in practice?

In the latest from Perspectives, our thought leadership series, Jack Pouderoyen, our Head of Digital Asset Strategy, sets out why interoperability is critical to scaling tokenised deposits globally.

Read now: https://t.co/7Sqqfb7xXj

#Interoperability #DigitalAssets

[PΣPP {X} @_MrYoshi]

@thiagoTF @SMQKEDQG No demmand without interoperability.

[Swords @PropheticSwords]

$XLM will capture much greater than 1% of value. And $SHX is right alongside that 😮‍💨

[PΣPP {X} @_MrYoshi]

Liquid 💵💧

[Ripple @Ripple]

More than 2 billion people worldwide lack access to safe water at home.💧 Addressing the global water crisis requires collective action.

We're proud to join @Water in support of Get Blue, a campaign helping expand access to safe water for communities around the world.

Find out how @Water is using $RLUSD to make a greater impact where it's needed most. https://t.co/wvcF2ws5QN

[Moon @moondailys]

Conjunction of Mercury, Venus and Jupiter

[Mr PitBull Stories @MrPitbull07]

In the summer of 2010, David Fajgenbaum was everything a young man could hope to be.
He had been a Division I college quarterback. He spoke multiple languages. He was in his third year at one of America's top medical schools, the University of Pennsylvania. He had his whole life mapped out in front of him.
Then his body turned on him.
Almost overnight, his organs began failing. His lymph nodes swelled. He was exhausted beyond anything he had ever felt. Within days, he was rushed to the emergency room. Weeks of testing followed. Finally, doctors gave it a name: Castleman disease — a rare and catastrophic condition where the immune system attacks the body's own organs.
There was no cure. There was barely a treatment.
A priest came to his hospital room and read his last rites.
David said goodbye to his family.
Then, somehow, an aggressive round of chemotherapy pulled him back from the edge.
But it didn't hold. Within three years, he collapsed again. And again. And again. Five times in total, he came to the edge of death. Five times, chemotherapy bought him a little more time.
After the fifth collapse, his doctors sat with him and said the words no patient wants to hear: his body had received the maximum amount of chemotherapy a human being can survive. If he relapsed again, there would be nothing left to give him.
He would die.
Most people, hearing that, would have spent whatever time remained saying goodbye.
David Fajgenbaum picked up a medical journal.
From his hospital bed, between treatments, he began doing something no patient had ever done before — systematically studying his own disease with the full knowledge of a trained physician. He analyzed thousands of pages of his own medical records. He tested his own blood samples, looking for patterns invisible to everyone else because no one else had both the data and the desperate motivation to find them.
And he found something.
In his lymph node samples, a specific protein signaling pathway called mTOR was firing at abnormally high levels — essentially sending the immune system into a frenzy that destroyed his own organs. It was a clue no one had spotted because no one had looked in quite that way before.
Then he searched for something that could stop it.
He found it in an unlikely place: a medication called sirolimus, already approved and available, commonly used to prevent organ rejection after kidney transplants. No one had ever tried it for Castleman disease. But on paper, its mechanism was a near-perfect match for what David had found in his own blood.
Under his doctor's supervision, he began taking it.
Within days, his symptoms vanished.
Not improved. Vanished.
The man doctors had given up on walked out of the hospital. He finished medical school. He married his girlfriend Caitlin. He became a father. He became one of the youngest faculty members ever to receive tenure at Penn Medicine.
And then he turned around to face everyone still waiting in the dark.
He founded the Castleman Disease Collaborative Network, building the first global research effort for a disease that had none. He launched Every Cure — an organization that uses artificial intelligence to search all existing approved drugs for hidden matches with diseases that currently have no treatment. The idea is simple and revolutionary: there are over 1,500 approved drugs in the world and over 7,000 diseases with no treatment. The cures may already exist. They just haven't been matched yet.
Over 15 years, Fajgenbaum and his partners have helped advance 28 repurposed drugs — 14 directly led by him. MedicalXpress
A priest once came to read him his last rites.
Today, David Fajgenbaum has authored over 100 scientific papers, appeared on TIME's list of the world's most influential people in health, and continues to take his small sirolimus tablet every single morning the pill he found himself, in the darkest room of his life, when no one else was looking.
He didn't wait to be saved.

[Tom @Tom0nChain]

Never forget @BankofAmerica has a $XRP patent.